CoChat
Sign Up
Cited by 123Schizophrenia research and treatmentPharmacology and Obesity TreatmentDiabetes Treatment and Management

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis

Open access
Siskind, Dan J., Leung, Janni, Russell, Anthony W., Wysoczanski, Daniel, Kisely, Steve·2016·PLoS ONE
DOI 10.1371/journal.pone.0156208PMC PMC4909277
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Although clozapine is the gold-standard for treatment refractory schizophrenia, it has the worst metabolic profile of all antipsychotics. This is partly mediated by clozapine's impact on glucagon-like peptide (GLP-1). There is an absence of robust evidence for effective treatments for clozapine associated weight gain and metabolic syndrome. Metformin, with its role in increasing GLP-1 may aid weight loss among people on clozapine. METHODS: We conducted a systematic-review and meta-analysis of metformin versus placebo for change in weight and metabolic syndrome for people on clozapine without diabetes mellitus. We searched the Cochrane Schizophrenia Group's trial register, Pubmed and Embase, as well as the following Chinese databases: the Chinese Biomedical Literature Service System and China Knowledge Resource Integrated Database. This was supplemented by hand searches of key papers. RESULTS: Eight studies, of which three were from Chinese databases, with 478 participants were included. We found that metformin was superior to placebo in terms of weight loss (-3.12kg, 95%CI -4.88kg to -1.37kg) and BMI (-1.18kg/m2, 95%CI -1.76kg/m2 to -0.61kg/m2). Metformin significantly improved three of the five components of metabolic syndrome; waist circumference, fasting glucose and triglycerides. Sensitivity analysis on study quality and duration did not greatly impact results. CONCLUSIONS: Metformin led to clinically meaningful weight loss among people on clozapine, and may reduce the rates of metabolic syndrome. Inclusion of metformin into the treatment protocols of people on clozapine, as tolerated, should be considered. TRIAL REGISTRATION: PROSPERO registration number: CRD42015029723.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0156208

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 32 references

Research works printed but not linked: 2

  1. H Liu, 2012, Effects of metformin hydrochloride on body mass and blood sugar of convalescence schizophrenics on clozapine, J Clin Psychosom Dis, 18, 97
  2. W Wu, 2014, Metformin hydrochloride auxiliary clozapine impact on patients weight and blood sugar treatment refractory schizophrenia, Chinese People's Health, 26, 68

Cited by

Sorted by citations

Items 101–123 of 123

Related

See all

Metadata

Authors
Siskind, D. J., Leung, J., Russell, A. W., Wysoczanski, D., & Kisely, S.
Affiliations
  • The University of Queensland (AU)
  • Griffith University (AU)
Corresponding author
Siskind, Dan J.
ORCID
Venue
PLoS ONE
Publisher
Public Library of Science (PLoS)
Published
2016-06-15
Volume
11
Issue
6
Pages
e0156208
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0156208
PMC
PMC4909277
OpenAlex
W2436128242
Cited by
122
References
32
Citations by year
2026: 7 · 2025: 13 · 2024: 10 · 2023: 9 · 2022: 15 · 2021: 22 · 2020: 14 · 2019: 10 · 2018: 12 · 2017: 7 · 2016: 3
FWCI
1.53
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • Griffith Research Online (submittedVersion, cc-by)
Funders
University of Queensland
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
metformin, clozapine, obesity, metabolic syndrome, weight loss, glucagon-like peptide-1, antipsychotic adverse effects, treatment-resistant schizophrenia, body mass index, waist circumference, fasting blood glucose, triglycerides
MeSH terms
Blood Glucose, Body Weight, Clozapine, Fasting, Humans, Hypoglycemic Agents, Metformin, Obesity, Schizophrenia, Antipsychotic Agents, Triglycerides, Weight Gain, Body Mass Index, Randomized Controlled Trials as Topic, Treatment Outcome, Metabolic Syndrome, Waist Circumference

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review